vTv Therapeutics (VTVT) Invested Capital (2014 - 2026)

vTv Therapeutics has disclosed Invested Capital across 13 years of filings, most recently posting $90.0 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $90.0 million, up 911.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.0 million (up 911.12% YoY), and the FY2025 annual result was $64.4 million, up 350.58% from the prior year.
• Invested Capital came in at $90.0 million for Q1 2026 at vTv Therapeutics, up from $64.4 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $90.0 million in Q1 2026 to a low of -$25.3 million in Q2 2023.
• The 5-year median for Invested Capital is $2.4 million (2025), against an average of $10.4 million.
• Across the five-year window, Invested Capital sank 196.54% in 2023 and jumped 911.12% in 2026, its largest moves.
• vTv Therapeutics' Invested Capital stood at -$10.7 million in 2022, then sank by 129.8% to -$24.7 million in 2023, then soared by 157.95% to $14.3 million in 2024, then soared by 350.58% to $64.4 million in 2025, then jumped by 39.61% to $90.0 million in 2026.
• The last three Invested Capital figures came in at $90.0 million (Q1 2026), $64.4 million (Q4 2025), and $70.5 million (Q3 2025), per Business Quant data.